EPHA7 and neoplasm: Among the 20 prostate carcinoma specimens, 13 (65.0%) exhibited undetectable or weak ephrinA5 immunostaining, and 40.0% (8/20) of the tumor tissues had no intense immunostaining of the EphA7 protein (Figure 7a).